View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
February 24, 2020

ReNeuron’s hRPC stem cell therapy yields positive results

ReNeuron Group has reported positive long-term efficacy data from the ongoing Phase I/II clinical trial of human retinal progenitor cell (hRPC) stem cell therapy in patients with retinitis pigmentosa (RP).

ReNeuron Group has reported positive long-term efficacy data from the ongoing Phase I/II clinical trial of human retinal progenitor cell (hRPC) stem cell therapy in patients with retinitis pigmentosa (RP).

RP is a group of hereditary eye diseases that cause progressive loss of sight and blindness. hRPC therapy is intended to preserve existing photoreceptors to reduce or potentially stop further vision loss.

In October last year, interim efficacy data from the trial revealed sustained clinically relevant visual acuity improvements, compared to baseline, in a group of participants.

According to the latest long-term data, the meaningful clinical effect from the therapy candidate continued at all time points through to twelve months following treatment.

ReNeuron Group CEO Olav Hellebø said: “We remain greatly encouraged by the data from the Phase I/IIa clinical study of our hRPC cell therapy candidate in patients with RP.

“The longer-term follow-up data are particularly noteworthy, demonstrating that the therapy appears to maintain its beneficial effects out to at least one year post-treatment.”

The company has filed a protocol amendment with the US Food and Drug Administration (FDA) to expand the Phase I/IIa trial.

The aim is to enrol up to an additional of nine patients in the Phase IIa part of the study. New participants will be treated with a dose of two million hRPC cells, which will be compared to the one million cells dose used in the trial so far.

The updated protocol will enable a greater range of pre-treatment baseline visual acuity. Data from the expanded segment is expected to be reported later this year.

ReNeuron has also submitted an application to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to open the trial to the Oxford Eye Hospital.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena